{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:02:21Z","timestamp":1740135741840,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005927","name":"Daiichi Sankyo Foundation of Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00380-024-02418-1","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T05:02:00Z","timestamp":1716267720000},"page":"958-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of acute thrombus regression effect of edoxaban for deep vein thrombosis in patients with cancer: a single-center prospective observational study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-537X","authenticated-orcid":false,"given":"Shinji","family":"Hisatake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"2","key":"2418_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA (2021) Venous and arterial thromboembolism in patients with cancer: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(2):173\u2013190","journal-title":"JACC CardioOncol"},{"issue":"3","key":"2418_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634","journal-title":"J Thromb Haemost"},{"key":"2418_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1182\/asheducation-2013.1.684","volume":"2013","author":"GC Connolly","year":"2013","unstructured":"Connolly GC, Francis CW (2013) Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program 2013:684\u2013691","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2418_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","volume":"103","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, S\u00f8ndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, S\u00f8rensen HT (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997\u20132006. Br J Cancer 103(7):947\u2013953","journal-title":"Br J Cancer"},{"issue":"6","key":"2418_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809\u2013815","journal-title":"Arch Intern Med"},{"issue":"10","key":"2418_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB Abdol Razak","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel) 10(10):380","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2418_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.25714","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH (2011) Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 117(7):1334\u20131349","journal-title":"Cancer"},{"issue":"3","key":"2418_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ccl.2004.04.002","volume":"22","author":"VF Tapson","year":"2004","unstructured":"Tapson VF (2004) Acute pulmonary embolism. Cardiol Clin 22(3):353\u2013365","journal-title":"Cardiol Clin"},{"issue":"9","key":"2418_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O\u2019Connell C, Carrier M (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891\u20131894","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2418_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"6","key":"2418_CR11","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545\u2013e608","journal-title":"Chest"},{"issue":"10","key":"2418_CR12","first-page":"1181","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, Fertrin KY, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Ibrahim I, Kraut E, Leavitt AD, Lee A, Lee JT, Lim M, Mann J, Martin K, McMahon B, Moriarty J, Morton C, Ortel TL, Paschal R, Schaefer J, Shattil S, Siddiqi T, Sudheendra D, Williams E, Hollinger L, Nguyen MQ (2021) Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(10):1181\u20131201","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2418_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K (2023) Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 34(5):452\u2013467","journal-title":"Ann Oncol"},{"issue":"21","key":"2418_CR14","first-page":"1665","volume":"148","author":"Y Yamashita","year":"2023","unstructured":"Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T (2023) Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT Study): an open-label, multicenter. Randomized Clinical Trial Circulation 148(21):1665\u20131676","journal-title":"Randomized Clinical Trial Circulation"},{"issue":"1","key":"2418_CR15","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap \u00c1F, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37-46","journal-title":"Lancet Haematol"},{"issue":"20","key":"2418_CR16","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2418_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B\u00fcller HR (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"17","key":"2418_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"issue":"2","key":"2418_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2418_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mah\u00e9 I, Pernod G, Elias A, Couturaud F, Falvo N, Sevestre MA, Ray V, Burnod A, Brebion N, Roy PM, Timar-David M, Aquilanti S, Constans J, Bura-Rivi\u00e8re A, Brisot D, Chatellier G, Sanchez O, Meyer G, Girard P, Mismetti P (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 161(3):781\u2013790","journal-title":"Chest"},{"issue":"3","key":"2418_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5770\/cgj.23.463","volume":"23","author":"K Rockwood","year":"2020","unstructured":"Rockwood K, Theou O (2020) Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J 23(3):210\u2013215","journal-title":"Can Geriatr J"},{"issue":"7","key":"2418_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/(SICI)1097-0096(199709)25:7<343::AID-JCU1>3.0.CO;2-A","volume":"25","author":"M Dauzat","year":"1997","unstructured":"Dauzat M, Laroche JP, Deklunder G, Ayoub J, Qu\u00e9re I, Lopez FM, Janbon C (1997) Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends and controversies. J Clin Ultrasound 25(7):343\u2013358","journal-title":"J Clin Ultrasound"},{"issue":"6","key":"2418_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1253\/circj.CJ-16-1012","volume":"81","author":"S Hisatake","year":"2017","unstructured":"Hisatake S, Kabuki T, Kiuchi S, Oka T, Dobashi S, Fujii T, Iwasaki Y, Ikeda T (2017) Short-term subcutaneous fondaparinux and oral edoxaban for acute venous thromboembolism. Circ J 81(6):855\u2013861","journal-title":"Circ J"},{"issue":"2","key":"2418_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jjcc.2016.10.013","volume":"70","author":"T Kabuki","year":"2017","unstructured":"Kabuki T, Nakanishi R, Hisatake S, Fujii T, Dobashi S, Wakakura S, Kiuchi S, Fujino T, Ikeda T (2017) A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism. J Cardiol 70(2):163\u2013168","journal-title":"J Cardiol"},{"issue":"1","key":"2418_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202\u2013204","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2418_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1253\/circj.CJ-10-1036","volume":"75","author":"M Nakamura","year":"2011","unstructured":"Nakamura M, Okano Y, Minamiguchi H, Munemasa M, Sonoda M, Yamada N, Hanzawa K, Aoyagi N, Tsujimoto H, Sarai N, Nakajima H, Kunieda T (2011) Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circ J 75(6):1424\u20131432","journal-title":"Circ J"},{"issue":"3","key":"2418_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2418_CR28","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"1","key":"2418_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","volume":"100","author":"N Ru\u00edz-Gim\u00e9nez","year":"2008","unstructured":"Ru\u00edz-Gim\u00e9nez N, Su\u00e1rez C, Gonz\u00e1lez R, Nieto JA, Todol\u00ed JA, Samperiz AL, Monreal M (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100(1):26\u201331","journal-title":"Thromb Haemost"},{"issue":"5","key":"2418_CR30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","volume":"48","author":"FA Klok","year":"2016","unstructured":"Klok FA, H\u00f6sel V, Clemens A, Yollo WD, Tilke C, Schulman S, Lankeit M, Konstantinides SV (2016) Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 48(5):1369\u20131376","journal-title":"Eur Respir J"},{"issue":"6","key":"2418_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2169\/internalmedicine.0296-22","volume":"62","author":"A Yamashita","year":"2023","unstructured":"Yamashita A, Hisatake S, Kiuchi S, Kabuki T, Ikeda T (2023) Effectiveness of fondaparinux in the japanese population with acute venous thromboembolism -a study comparing patients with and without cancer. Intern Med 62(6):821\u2013831","journal-title":"Intern Med"},{"issue":"1","key":"2418_CR32","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1186\/s12885-022-10403-y","volume":"22","author":"M Nakamura","year":"2022","unstructured":"Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y (2022) Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study. BMC Cancer 22(1):1322","journal-title":"BMC Cancer"},{"issue":"4","key":"2418_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1358863X16645853","volume":"21","author":"G Piazza","year":"2016","unstructured":"Piazza G, Mani V, Goldhaber SZ, Grosso MA, Mercuri M, Lanz HJ, Schussler S, Hsu C, Chinigo A, Ritchie B, Nadar V, Cannon K, Pullman J, Concha M, Schul M, Fayad ZA (2016) Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation\/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vasc Med 21(4):361\u2013368","journal-title":"Vasc Med"},{"issue":"1","key":"2418_CR34","doi-asserted-by":"publisher","first-page":"21569","DOI":"10.1038\/s41598-022-26150-w","volume":"12","author":"S Takai","year":"2022","unstructured":"Takai S, Nakanishi N, Yokota I, Imai K, Yamada A, Kawasaki T, Kasahara T, Okada T, Sawada T, Matoba S (2022) Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study. Sci Rep 12(1):21569","journal-title":"Sci Rep"},{"issue":"4","key":"2418_CR35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00380-018-1283-5","volume":"34","author":"D Sato","year":"2019","unstructured":"Sato D, Ikeda S, Koga S, Yamagata Y, Eguchi M, Yonekura T, Tsuneto A, Yoshimuta T, Koide Y, Kawano H, Maemura K (2019) Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and\/or older age. Heart Vessels 34(4):678\u2013687","journal-title":"Heart Vessels"},{"issue":"1","key":"2418_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cancers11010048","volume":"11","author":"F Scott\u00e9","year":"2019","unstructured":"Scott\u00e9 F, Leroy P, Chastenet M, Aumont L, Benatar V, Elalamy I (2019) Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management. Cancers (Basel) 11(1):48","journal-title":"Cancers (Basel)"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-024-02418-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-024-02418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T12:04:23Z","timestamp":1729253063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-024-02418-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1007\/s00380-024-02418-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. I. received research funds and lecture fees from Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., and Bristol\u2010Myers Squibb. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Toho University Omori Hospital, Japan (application number M19004). UMIN ID:\u3000UMIN000036958.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB information"}},{"value":"The de-identified participant data will not be shared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}